Type 1 diabetes patients are denied access to NHS specialists
NHS commissioning policies stop people with type 1 diabetes from gaining access to essential specialist services, medical experts have warned.
Final CCGs submit applications
The final ‘wave’ of clinical commissioning groups have submitted their applications for authorisation with the NHS Commissioning Board (NHS CB).
Bridge over troubled healthcare
How will Public Health England bring together the NHS and local government?
CQC improving after difficult start
The Care Quality Commission has experienced “serious difficulties” in its first 18 months, according to a National Audit Office report.
NICE launches QOF consultation
The National Institute of Health and Clinical Excellence (NICE) has launched a public consultation on the new indicators for the 2013/14 Quality and Outcomes Framework (QOF).
Public ignoring flu jab
The Government has claimed people who ignore receiving the seasonal flu vaccine are playing “Russian roulette with their lives”.
New online register launched by EMA and ENCePP
The EMA and the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) have launched the E-Register of Studies.
The new UK pharma Code
Dr Powar asks how the changes to the ABPI Code will impact pharma's customer relationships.
What’s Up Doc?
With the advent of revalidation, doctors will be assessed for fitness to practice every five years. Dr Gerard Panting explains how the pharma industry...
Decoding The NHS
A Trust comprising of 3 hospitals were under considerable ‘bombardment’ from COX2 companies pushing considerable data and marketing materials. One company managed to involve...
Latest articles
NHSX: Combining the best talent from government, the NHS and industry.
A new joint unit, NHSX, will be created to bring the benefits of modern technology to every patient and clinician. It will combine the...
Sygnature Discovery makes key appointments
Sygnature Discovery has made two key appointments, Dr Allan Jordan and Ms Louisa Jordison. Ms Jordison joins the independent integrated drug discovery and pre-clinical services...
KEYTRUDA results published for advanced renal cell carcinoma
MSD has announced presentation of the full results from the pivotal Phase 3 KEYNOTE-426 trial investigating KEYTRUDA, MSD’s anti-PD-1 therapy, in combination with Inlyta...